Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin

NCT00242372 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00242372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2004
Completion date
March 31, 2006
Enrollment
370
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus